Synapse - Lindsey Roeker

Search Within

Lindsey Elizabeth Roeker

Results (146)

Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings

Meeting Abstract

Valtis, Y.; Nemirovsky, D.; Derkach, A.; Roeker, L. E.; Sharan, S.; Kabel, C.; Ortiz, R.; Geyer, M. B.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Journal Article

Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
The Lancet Haematology (2024)

Fulltext@MSK | Save

A fresh look at covalent BTK inhibitor resistance

Editorial

Roeker, L. E.
Blood (2024)

Fulltext@MSK | Save

Hypertension treatment for patients receiving ibrutinib: A multicenter retrospective study

Journal Article

Samples, L.; Voutsinas, J.; Fakhri, B.; Khajavian, S.; Spurgeon, S.; Stephens, D.; Skarbnik, A.; Mato, A.; Broome, C.; Gopal, A.; more...
Blood Advances (2024)

Fulltext@MSK | Save

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Journal Article

Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
Science (2024)

Fulltext@MSK | Save

A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation

Meeting Abstract

Goldberg, A. D.; Samaniego, F.; Ohanian, M.; Koller, P. B.; Chandhok, N. S.; Sadiq, A. A.; Mahadevan, D.; Cherry, M. A.; Altman, J. K.; Burke, J. M.; more...
Blood (2023)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) among patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving pirtobrutinib: Analysis from the BRUIN phase 1/2 study

Meeting Abstract

Coombs, C. C.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Tam, C. S.; Seymour, J. F.; Shah, N. N.; more...
Blood (2023)

Fulltext@MSK | Save

Fixed-duration pirtobrutinib combined with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Updated results, including MRD data, from the BRUIN phase 1b study

Meeting Abstract

Roeker, L. E.; Woyach, J. A.; Cheah, C. Y.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M.; Tsai, D. E.; Nair, B.; Wang, C.; more...
Blood (2023)

Fulltext@MSK | Save

A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation

Meeting Abstract

Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study

Meeting Abstract

Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
Blood (2023)

Fulltext@MSK | Save